What is it about?
Liposteroid (dexamethasone palmitate), a lipid emulsion containing dexamethasone, was developed in Japan. Recently, Japanese researchers reported the clinical utility of liposteroid in the treatment of macrophage activation syndrome, graft-versus-host disease, hemophagocytic lymphohistiocytosis, and pulmonary hemosiderosis.
Featured Image
Why is it important?
Liposteroid provides greater efficacy and much less risk for systemic adverse effects than dexamethasone, because the lipid emulsion is easily taken up by phagocytes.
Perspectives
By accumulating case reports from all over the world regarding the use of liposteroid therapy for treatment of macrophage activation, there is some evidence that this agent may be effective for reducing side effects in patients with macrophage activation.
Hiroyuki Wakiguchi
Yamaguchi Daigaku
Read the Original
This page is a summary of: Clinical utility of the liposteroid therapy: Potential effects on the macrophage activation, Japanese Journal of Clinical Immunology, January 2016, Japan Society for Clinical Immunology,
DOI: 10.2177/jsci.39.190.
You can read the full text:
Resources
Contributors
The following have contributed to this page
